Key Segmentation:
By Therapy Type
-
Radiation Therapy
-
Immunotherapy
-
Targeted Therapy
-
Gene Therapy
-
Chemotherapy
-
Surgical Resection
-
Transpupillary Thermotherapy
-
Combination Therapy
By Drug Class
-
Immune Checkpoint Inhibitors
-
Protein Kinase Inhibitors
-
Antimetabolites
-
Oncolytic Viruses
-
Others
By Disease Stage
-
Primary Uveal Melanoma
-
Metastatic Uveal Melanoma (Liver)
-
Other Metastatic Sites
By Route of Administration
-
Intravenous
-
Oral
-
Intravitreal
-
Localized Implant Delivery
By End Use
-
Hospitals
-
Cancer Treatment Centers/Ophthalmology Centers
-
Academic & Research Institutes
-
Others
By Patient Age Group
-
Adult Patients
-
Pediatric Patients
-
Geriatric Patients
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
Leading companies include Immunocore Holdings, Delcath Systems, IDEAYA Biosciences, Servier, Aura Biosciences, Merck & Co., Bristol Myers Squibb, Eli Lilly, Novartis, and Bayer, among others.
Key opportunities include extending targeted therapy beyond the HLA-A*02:01-positive population, refining ocular drug-delivery platforms, advancing adjuvant treatment trials for high-risk primary disease, and expanding market access across emerging markets such as Brazil.
Growth is primarily driven by the first-in-class survival benefit demonstrated by tebentafusp for HLA-A*02:01-positive metastatic disease, combined with rising global incidence and expanding orphan-drug regulatory incentives.
By Therapy Type, Radiation Therapy dominates the market with approximately 34.80% share in 2025, supported by its established role in eye-preserving local tumor control for primary disease.
North America dominates the market with approximately 29.05% share in 2025, supported by FDA leadership on orphan-drug incentives and a dense network of ocular oncology specialists.
